NCT00938158View on ClinicalTrials.gov

A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 5, 2009

Primary Completion Date

April 12, 2011

Study Completion Date

April 12, 2011

Conditions
Diabetes Mellitus, Type 2
Interventions
BIOLOGICAL

albiglutide

single dose of subcutaneously injected albiglutide

Trial Locations (7)

2193

GSK Investigational Site, Parktown

32809

GSK Investigational Site, Orlando

33169

GSK Investigational Site, Miami

36207

GSK Investigational Site, Anniston

55404

GSK Investigational Site, Minneapolis

70806

GSK Investigational Site, Baton Rouge

07129

GSK Investigational Site, Somerset West

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00938158 - A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects. | Biotech Hunter | Biotech Hunter